FDA approves combo for ESR1-mutated breast cancer - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

  • By

  • Kathryn Wighton

  • September 21, 2026

  • 2 min

Share

Original Source(s)

FDA approves combo for ESR1-mutated breast cancer

  • by Kathryn Wighton

  • September 21, 2026

Related Content

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Women Overdue for Cancer Screenings

More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.

Medical Oddities: Something Viral is Lurking in the Dust

Everyday things like yawns, tea, dust, and kimchi suddenly look medically important.